MedTech Resources

FDA Clearance Tracker · P200048

IsoPSA Assay

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this decision)Source: openFDAMethods & limitations

PMABreakthrough

Decided

Nov 28, 2025

Approved

Time to decision

1,796 days

Received Dec 28, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P200048
Device name
IsoPSA Assay
Applicant location
Cleveland, OH
Received
Dec 28, 2020
Decided
Nov 28, 2025
Decision
Approved
Supplements
1 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QRF

FDA's approval statement

As written in FDA's record.

Approval for the IsoPSA Assay.The IsoPSA Assay is an in vitro test system that combines the results of total Prostate Specific Antigen (PSA) (Elecsys, Roche Diagnostics) and free PSA (Elecsys, Roche Diagnostics) from partitioned heparinized plasma into a single numerical index. The IsoPSA Assay is indicated for use in conjunction with other patient information to aid in detection of high-grade prostate cancer (Grade Group >= 2; Gleason score >= 7) in men >= 50 years of age, with total PSA levels >= 4.0 to =< 10.0 ng/mL for whom a biopsy is being considered by a urologist based on current standard of care, before consideration of IsoPSA Assay results.Prostatic biopsy is required for the diagnosis of cancer.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code QRF. The earliest in FDA's data is P190022, decided Dec 7, 2021.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Cleveland Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.